Efficacy News and Research

RSS

Fibrex medical reports positive phase II results for peptide for the treatment of reperfusion injury

Fibrex Medical has announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany.

2 Sep 2008

First patient enrolled in study evaluating S.M.A.R.T. Nitinol self-expandable stent

Cordis Corporation has announced the first patient enrollment in the STROLL trial, which will evaluate the safety and efficacy of the S.M.A.R.T. Nitinol Self-Expandable Stent System in treating patients with obstructive superficial femoral artery (SFA) disease, also known as SFA atherosclerosis.

2 Sep 2008

Overcoming poor response to standard oral antiplatelet agents

Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.

2 Sep 2008

Results from the Simvastatin and Ezetimibe in aortic stenosis study

The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis.

2 Sep 2008

MorphoSys announces publication of first MOR103 data

MorphoSys AG announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".

2 Sep 2008

Earwax removal - new guidelines

The American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) will issue the first comprehensive clinical guidelines to help health care practitioners identify patients with cerumen (commonly referred to as earwax) impaction. The guidelines emphasize evidence-based management of cerumen impaction by clinicians, and inform patients of the purpose of ear wax in hearing health.

1 Sep 2008

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Antiangiogenic and anti-inflammatory drugs: are they safe?

Since Rofecoxib (Vioxx) was withdrawn from the worldwide market based on the safety findings of the Adenomatous Polyp Prevention on Vioxx (APPROVe) study, the uncertainty around the cardiovascular safety of NSAIDs and COX-2 inhibitors remains and leaves practitioners with difficult management decisions for the hundreds of millions of patients worldwide who continue to require pain-relieving therapy to maintain an acceptable quality of life.

1 Sep 2008

Transcatheter aortic valve replacement - a new frontier in cardiovascular medicine

Replacing heart valves without the substantial trauma of opening the chest and the heart were little known concepts until the groundbreaking pulmonary and aortic transcatheter valve replacements performed during 2000 and 2002, respectively by Philipp Bonhoeffer and Alain Cribier.

1 Sep 2008

Percutaneous mitral valve repair

The scope of percutaneous cardiac therapy has expanded from percutaneous coronary and peripheral intervention to percutaneous valve intervention, first used in the mid eighties.

1 Sep 2008

New generation drug-eluting stent demonstrates equivalent efficacy to market leader in 'real world'

In the first study of its kind, a drug-eluting stent (DES) with a biodegradable polymer applied only to the outer surface has been demonstrated as safe and effective as one of the most established and widely used types of DES with a durable polymer, in equivalent conditions to everyday clinical practice.

1 Sep 2008

Drug eluting stents: New elements in the debate

Results announced at the 2006 ESC meeting in Barcelona questioned the long-term safety of drug eluting stents (DES) and sparked intense discussion.

31 Aug 2008

Infectious Disease Research Institute receives $6.3 million NIAID grant to study TB vaccine

Seattle's Infectious Disease Research Institute on Tuesday announced it has received a $6.3 million grant from NIH's National Institute of Allergy and Infectious Diseases to study a new tuberculosis vaccine, the Puget Sound Business Journal reports (Puget Sound Business Journal, 8/27).

29 Aug 2008

Algeta reports positive phase II data on pain palliation with Alpharadin

Algeta ASA today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose.

28 Aug 2008

Recent advances make cervical cancer control in developing world feasible for first time

Recent advances in cervical cancer prevention mean that controlling the disease in developing countries is becoming feasible for the first time, experts say.

28 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Potential new targets for antidepressants

The news about antidepressant medications over the past several years has been mixed. The bad news from large multicenter studies such as STAR*D is that current antidepressant medications are effective, but not as effective as one might hope. Thus, there is a significant need for new treatment mechanisms for depression. On that front, there has been mixed news as well.

27 Aug 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer?

Prof. Eliezer Flescher of The Sackler Faculty of Medicine, Tel Aviv University thinks so. He and his colleagues have developed an anti-cancer drug based on a decade of research into the commercial applications of the compound Jasmonate, a synthetic compound derived from the flower itself.

25 Aug 2008

AIDS Healthcare Foundation blasts GlaxoSmithKline print advertisements that promote fear of HIV treatment

AIDS Healthcare Foundation (AHF) is blasting British multi-national drug giant GlaxoSmithKline (GSK) for a recent series of direct-to-consumer print advertisements that, under the guise of patient education, capitalize on patients' fears of HIV treatment.

25 Aug 2008

Efficacy News and Research

Fibrex medical reports positive phase II results for peptide for the treatment of reperfusion injury

First patient enrolled in study evaluating S.M.A.R.T. Nitinol self-expandable stent

Overcoming poor response to standard oral antiplatelet agents

Results from the Simvastatin and Ezetimibe in aortic stenosis study

MorphoSys announces publication of first MOR103 data

Earwax removal - new guidelines

Advances in the management of diabetes mellitus

Antiangiogenic and anti-inflammatory drugs: are they safe?

Transcatheter aortic valve replacement - a new frontier in cardiovascular medicine

Percutaneous mitral valve repair

New generation drug-eluting stent demonstrates equivalent efficacy to market leader in 'real world'

Drug eluting stents: New elements in the debate

Infectious Disease Research Institute receives $6.3 million NIAID grant to study TB vaccine

Algeta reports positive phase II data on pain palliation with Alpharadin

Recent advances make cervical cancer control in developing world feasible for first time

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Potential new targets for antidepressants

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer?

AIDS Healthcare Foundation blasts GlaxoSmithKline print advertisements that promote fear of HIV treatment

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News